MedWatch

Semaglutide fails in phase II trial within fatty liver disease

Novo Nordisk joins a string of other companies in acknowledging that a fatty liver can be hard to treat. On Wednesday, the company reports that its NASH therapy has failed in a phase II study as a monotherapy against the disease.

Photo: POOL New/REUTERS / X80003

Non-alcoholic fatty liver disease, also known as NASH, has proven itself to be somewhat of a headache for several companies trying to develop treatments for the disease, and Novo Nordisk might be the latest addition to the group.

On Wednesday, the Danish pharmaceutical company announced that it has completed a 48-week long phase II trial of its molecule semaglutide as a treatment for NASH. The candidate was incapable of demonstrating an effect on the disease, though that the drug was well-tolerated by patients with the serious end-stage NASH complication, cirrhosis.

Read the whole article

Get 14 days free access.

No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Coloplast upgrades growth expectations following acquisition

Medtech firm Coloplast’s Q1 report for 2021/2022 brings a slight upward adjustment of the reported revenue growth outlook due to foreign exchange developments. Coloplast’s acquisition of Atos Medical is expected to contribute around 6 percent to organic growth.

Demant's surgical division loses president of 13 years

Oticon Medical, the implants division at hearing group Demant, is saying goodbye to President Jes Olsen, who is exiting his role in March after having spearheaded the business leg since 2008. Demant CEO Søren Nielsen is stepping in temporarily until a replacement is found.

Hearing aid market in US grew by 37 percent in 2021

Hearing aid manufacturers have had a good year following one of the worst in their recorded history, as sales in the US have gone up by 37 percent. The progress is mainly driven by the recovery of independent retailers, whereas public sales channel Veterans Affairs still lags behind.

Further reading

Related articles

Latest news

See all jobs